This article is more than 5 years old. Information may no longer be current.
Sunitinib active in meningioma
Click Here to Manage Email Alerts
Sunitinib demonstrated encouraging activity in patients with recurrent and progressive meningioma, according to results of a prospective, multicenter, single-arm phase 2 study.
The analysis included 36 patients with atypical (n=30) or anaplastic (n=6) meningioma.
Those enrolled in the primary cohort had surgery- and radiation-refractory grade II to grade III disease, a group for whom no proven effective therapy exists. The 13 patients enrolled in an exploratory cohort had grade I meningioma, hemangiopericytoma or hemangioblastoma.
All patients were heavily pretreated and had experienced a median of five disease recurrences (range, 2-10).
All patients received 50 mg daily sunitinib (Sutent, Pfizer) for 28 days.
Six-month PFS served as the primary outcome measure. Radiographic response rate, safety, PFS and OS served as secondary outcome measures.
The study — conducted by Thomas J. Kaley, MD, of the department of neurology at Memorial Sloan Kettering Cancer Center, and colleagues — met its primary endpoint, yielding a 6-month PFS rate of 42%.
Median PFS was 5.2 months (95% CI, 0.8-8.3) and median OS was 24.6 months (95% CI, 16.5-38.4).
Kaley and colleagues reported longer median PFS among patients with VEGFR-2–positive patients than VEGFR-2–negative patients (6.4 months vs. 1.4 months; P=.005).
Adverse events included one grade 5 intratumoral hemorrhage, two grade 3 CNS/intratumoral hemorrhages, one grade 4 CNS/intratumoral hemorrhage, one grade 3 thrombotic microangiopathy, one grade 4 thrombotic microangiopathy, and one grade 3 gastrointestinal perforation.
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.
Click Here to Manage Email Alerts